---
document_datetime: 2025-04-15 14:21:42
document_pages: 30
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mircera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: mircera-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 18.3606223
conversion_datetime: 2025-12-20 10:05:39.936359
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mircera

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0104/G            | This was an application for a group of variations. To delete the 40 micrograms/0,3 ml solution for injection in prefilled syringe strength from the Mircera marketing authorisation (EU/1/07/400/018). To delete the 60 micrograms/0,3 ml solution for | 30/01/2025                          |                                             | SmPC, Labelling and PL           |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The

CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | injection in prefilled syringe strength from the Mircera marketing authorisation (EU/1/07/400/019). C.I.7.b - Deletion of - a strength C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |                |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| II/0099/G | This was an application for a group of variations. B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.d.2.c - Change in test procedure for the finished product - Substantial change to or replacement of a biol/immunol/immunochemical test method or a method using a biol. reagent or replacement of a biol. reference preparation not covered by an approved protocol B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) | 11/07/2024 | n/a | Not applicable |

<div style=\"page-break-after: always\"></div>

| product - Other changes (including replacement B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.a - Change in and/or limits of the finished specification limits B.II.d.1.d - Change in and/or limits of the finished non-significant specification B.I.b.2.d - Change in starting material/reagent/intermediate change to or replacement biological/immunological/immunochemical method or a method using biological AS B.I.a.4.f - Change to in-process applied during the manufacture or replacement of an in-process safety or quality issue B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

<!-- image -->

| B.I.b.2.e - Change in starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.1.b - Change in and/or limits of an AS, material/intermediate/reagent specification limits B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in and/or limits of an AS,   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|         | specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter)   |            |     | significant   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------|
| IB/0103 | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 25/06/2024 | n/a |               |
| WS/2665 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.z - Quality change - Active substance - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 20/06/2024 | n/a |               |
| IB/0102 | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 14/06/2024 | n/a |               |

<div style=\"page-break-after: always\"></div>

|                    | changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                      |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| WS/2677            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test                                                                                                                    | 02/05/2024 | n/a |                                   |
| WS/2648/G          | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a test procedure (including replacement or addition) B.I.c.3.b - Change in test procedure for the immediate packaging of the AS - Other changes to a | 04/04/2024 | n/a |                                   |
| PSUSA/2017/ 202307 | Periodic Safety Update EU Single assessment - methoxy polyethylene glycol-epoetin beta                                                                                                                                                                                                                                                                                                                     | 07/03/2024 | n/a | PRAC Recommendation - maintenance |
| WS/2588            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new                                                                                                                        | 01/02/2024 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | specification parameter to the specification with its corresponding test method                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |                        |                                                                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------|
| IB/0096   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/12/2023 | 29/11/2024 | SmPC, Annex II and PL  |                                                                     |
| II/0092   | Extension of indication to include treatment of paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and to update the Instruction for Use in the Package Leaflet. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or | 22/06/2023 | 26/07/2023 | SmPC, Labelling and PL | Please refer to Scientific Discussion 'Mircera-H-C-000739- II-0092. |
| WS/2414/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.4.f - Change to in-process tests or limits applied during the manufacture of the AS - Addition                                                                                                                                                                                                                                                                          | 14/04/2023 | n/a        |                        |                                                                     |

<div style=\"page-break-after: always\"></div>

|           | replacement of an in-process test as a result of a or quality issue                                                                                                                                                                                                                                                                                                                                                      |            |            |    | or safety              |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------------------|
| N/0094    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                         | 15/03/2023 | 26/07/2023 | PL |                        |
| IA/0091/G | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 10/06/2022 | n/a        |    | changes to an approved |
| WS/2242   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                           | 02/06/2022 | n/a        |    |                        |
| IB/0089   | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                             | 30/03/2022 | n/a        |    |                        |
| IG/1462/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                       | 02/02/2022 | n/a        |    |                        |

<div style=\"page-break-after: always\"></div>

|                    | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure               |            |            |                                  |                                   |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------|
| IB/0087            | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                        | 08/12/2021 | 28/11/2022 | SmPC, Annex II, Labelling and PL |                                   |
| WS/2161            | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.1.k - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - New storage site of MCB and/or WCB | 02/12/2021 | n/a        |                                  |                                   |
| IA/0086/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                         | 03/11/2021 | n/a        |                                  |                                   |
| N/0084             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                      | 10/08/2021 | 28/11/2022 | PL                               |                                   |
| PSUSA/2017/ 202007 | Periodic Safety Update EU Single assessment - methoxy polyethylene glycol-epoetin beta                                                                                                                                                                                                | 11/03/2021 | n/a        |                                  | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| WS/1935   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a                                                                                                                                                                                                                                                                                                                                                                   | 28/01/2021   | n/a   | biological AS   |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------|
| WS/1914/G | This was an application for a group of variations following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a State | 19/11/2020   | n/a   | Member          |

<div style=\"page-break-after: always\"></div>

| IA/0082/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 10/11/2020   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| II/0078/G   | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.z - Change in control of the AS - Other | 05/06/2020   | n/a   |

<div style=\"page-break-after: always\"></div>

| IB/0079   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                            | 14/05/2020   | n/a        |                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------------|
| IB/0077   | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                | 30/03/2020   | n/a        |                              |
| II/0068   | C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                                                         | 31/10/2019   | 22/10/2020 | SmPC, Annex II and Labelling |
| IA/0076   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                         | 19/08/2019   | n/a        |                              |
| IB/0075   | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate          | 07/03/2019   | n/a        |                              |
| IG/1070   | B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State | 04/03/2019   | n/a        |                              |
| IG/1049/G | This was an application for a group of variations. B.I.a.2.z - Changes in the manufacturing process of the AS - Other variation B.I.b.1.c - Change in the specification parameters                                    | 17/01/2019   | n/a        |                              |

<div style=\"page-break-after: always\"></div>

|           | and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.III.2.b - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Change to comply with an update of the relevant monograph of the Ph. Eur. or national pharmacopoeia of a Member State                              |            |     |                                                             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------------------------------------------------|
| IG/0997/G | This was an application for a group of variations. B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor | 22/11/2018 | n/a |                                                             |
| WS/1481   | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                        | 22/11/2018 | n/a |                                                             |
| II/0067   | Submission of the final study results from Study NH 19707(Dolphin): an open-label, multi-center,                                                                                                                                                                                                                                                                                                                      | 15/11/2018 | n/a | Please refer to Scientific Discussion Mircera-H-C-00739-II- |

<div style=\"page-break-after: always\"></div>

|                    | multiple dose study to determine the optimum starting dose of intravenous Mircera for maintenance treatment of anemia in paediatric patients with chronic kidney disease on hemodialysis; listed in the paediatric investigation plan (PIP). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |            |                        | 0067.                             |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------------------------------|
| II/0070            | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                 | 25/10/2018 | n/a        |                        |                                   |
| N/0069             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                 | 09/08/2018 | 22/10/2020 | PL                     |                                   |
| T/0066             | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                              | 20/02/2018 | 16/03/2018 | SmPC, Labelling and PL |                                   |
| PSUSA/2017/ 201707 | Periodic Safety Update EU Single assessment - methoxy polyethylene glycol-epoetin beta                                                                                                                                                                                                                                                                           | 08/03/2018 | n/a        |                        | PRAC Recommendation - maintenance |
| IA/0065            | B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits                                                                                                                                                                                                                       | 15/12/2017 | n/a        |                        |                                   |
| II/0062/G          | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                               | 28/09/2017 | n/a        |                        |                                   |

<div style=\"page-break-after: always\"></div>

|           | B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |             |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| IAIN/0063 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                  | 22/09/2017 | 16/03/2018 | SmPC and PL |
| IA/0061/G | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits                          | 28/06/2017 | n/a        |             |
| IG/0736   | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                      | 19/10/2016 | n/a        |             |

<div style=\"page-break-after: always\"></div>

| N/0059    | Update of Annex IIIA to add the 2D barcode unique identifier according to QRD template vs 10. Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 18/08/2016   | 16/03/2018   | Labelling   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0057    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 16/11/2015   | 06/07/2016   | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| IA/0058   | B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/10/2015   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0055/G | This was an application for a group of variations. Update of section 4.8 of the SmPC to include the ADR 'Stevens Johnson syndrome / toxic epidermal necrolysis' under post-marketing experience, following the assessment of LEG 037. Further, section 4.8 has been revised in accordance with the current EU SmPC guidance to include a single table with adverse events from clinical studies and adverse reactions reported post-marketing. Furthermore, sections 4.2, 4.4 and 5.1 of the SmPC have been updated, upon request by PRAC following the assessment of LEG 032, to include an agreed class wording related to the risk of high cumulative doses in patients not responding to the treatment. The Package Leaflet has been updated accordingly. C.I.z - Changes (Safety/Efficacy) of Human and | 23/07/2015   | 06/07/2016   | SmPC and PL | Pooled post-hoc analyses of clinical studies of ESAs have been performed in chronic renal failure patients (on dialysis, not on dialysis, in diabetic and non-diabetic patients). A tendency towards increased risk estimates for all-cause mortality, cardiovascular and cerebrovascular events associated with higher cumulative ESA doses independent of the diabetes or dialysis status was observed. Patients should be monitored closely to ensure that the lowest approved effective dose of MIRCERA is used to provide adequate control of the symptoms of anaemia whilst maintaining a haemoglobin concentration below or at 12 g/dl (7.45 mmol/l). Caution should be exercised with escalation of MIRCERA doses in patients with chronic renal failure. In patients with a poor haemoglobin response to epoetins, alternative explanations for the poor response should be considered. |

<div style=\"page-break-after: always\"></div>

|                    | Veterinary Medicinal Products - Other variation C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                     |            |     |                                   |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IG/0573            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                       | 01/07/2015 | n/a |                                   |
| IA/0054/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.a - Change in supplier of packaging components or devices (when mentioned in the | 24/04/2015 | n/a |                                   |
| PSUSA/2017/ 201407 | Periodic Safety Update EU Single assessment - methoxy polyethylene glycol-epoetin beta                                                                                                                                                                                                                                                                | 12/02/2015 | n/a | PRAC Recommendation - maintenance |
| IG/0497            | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                       | 18/11/2014 | n/a |                                   |
| IA/0051/G          | This was an application for a group of variations. A.7 - Administrative change - Deletion of                                                                                                                                                                                                                                                          | 29/10/2014 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | sites - Change in test procedure for AS or material/reagent/intermediate - Minor to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |          | manufacturing B.I.b.2.a starting changes   |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|--------------------------------------------|
| IB/0050/G | This was an application for a group of variations. C.I.11.a - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of wording agreed by the competent authority C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing                                                                                                                                                                                                                                                                                                                                                                                                               | 22/09/2014 | 15/12/2014 | Annex II | authorisation, including                   |
| IB/0049/G | This was an application for a group of variations. B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits B.I.c.2.a - Change in the specification parameters and/or limits of the immediate packaging of the AS - Tightening of specification limits | 12/06/2014 | n/a        |          |                                            |

<div style=\"page-break-after: always\"></div>

| IAIN/0048   | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                 | 13/05/2014   | 15/12/2014   | SmPC, Labelling and PL   |                                   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------------------------|
| PSUV/0046   | Periodic Safety Update                                                                                                                                                                                                                                                                                                             | 05/02/2014   | n/a          |                          | PRAC Recommendation - maintenance |
| IB/0047     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                     | 19/12/2013   | 15/12/2014   | SmPC, Annex II and PL    |                                   |
| IG/0228     | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                     | 23/11/2012   | n/a          |                          |                                   |
| WS/0299     | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. minor changes to the manufacturing process of the active substance. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS | 20/09/2012   | n/a          |                          |                                   |
| II/0041/G   | This was an application for a group of variations. To add changes to the specifications and test procedure for the active substance. B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Change                                                                                                | 20/09/2012   | n/a          |                          |                                   |

<div style=\"page-break-after: always\"></div>

| (replacement) to a biological/immunological/ immunochemical test biological reagent for a B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|          | material/intermediate B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| A20/0039 | Pursuant to Article 20 of Regulation (EC) No 726/2004, the European Commission requested on 15 December 2011, the opinion of the CHMP on measures necessary to ensure the quality and the safe use of the above mentioned medicinal product further to the inspection findings at the manufacturing site Roche Carolina Inc. (RCI), Florence, in the United States of America (USA), to assess the impact thereof on the risk-benefit balance of Mircera and to give its opinion whether the marketing authorisation of this product should be maintained, varied, suspended or withdrawn. | 19/07/2012 | 20/09/2012 |                                  | Please refer to the assessment report : EMEA/H/C/739/A- 20/0039                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0037   | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 16/02/2012 | 15/05/2012 | SmPC, Annex II, Labelling and PL | Based on the review of the available information the CHMP is of the opinion that the quality, the safety and the efficacy of Mircera continues to be adequately and sufficiently demonstrated and considers that the benefit/risk profile of this medicinal product continues to be favourable. The CHMP recommends the renewal of the Marketing Authorisation for Mircera, subject to the conditions and obligations as laid down in Annex II to the Opinion. The CHMP recommends that the renewal be granted with unlimited validity The MAH is requested to submit yearly PSURs unless otherwise specified by the CHMP. |

<div style=\"page-break-after: always\"></div>

| IG/0161   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                                                                                                                   | 14/03/2012   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0125   | C.I.9.i - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) to a DDPS following the assessment of the same DDPS in relation to another medicinal product of the same MAH                                                                                                                                                                                                                                                                                                   | 06/12/2011   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| II/0035   | Update of section 4.8 \"Undesirable effects\" of the Summary of Product Characteristics (SmPC) to include \"thrombocytopenia\" as an adverse reaction following a review of spontaneous reports and uncontrolled post-marketing studies with Mircera. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH | 22/09/2011   | 20/10/2011 | SmPC        | Although the analysis of platelet counts in placebo- controlled studies showed that there was no difference between Mircera and placebo treatment, and that there was a lack of first-dose effect in patients in controlled clinical trials, an update of the ADVENT safety database showed 44 events of thrombocytopenia from spontaneous reports and uncontrolled post-marketing studies. Therefore the MAH proposed to amend section 4.8 of the SmPC to state that a clinically relevant reduction in platelet counts is attributable to Mircera administration, although the frequency of this adverse event is unknown. |
| II/0034   | Update of sections 4.4 \"Special warnings and precautions for use\" and 4.8 \"Undesirable effects\" of the Summary of Product Characteristics (SmPC) to include \"Pure Red Cell Aplasia\" (PRCA) as an adverse reaction. Section 2 of the Package Leaflet (PL) has been updated accordingly.                                                                                                                                                                                                                        | 22/09/2011   | 20/10/2011 | SmPC and PL | The first case of PRCA related to the use of Mircera confirmed by an independent external assessor was documented on the 21st of December 2010. Following such report, the MAH sought to include \"pure red cell aplasia\" as undesirable effect in sections 4.4 and 4.8 of the SmPC and Section 2 of the PL, as a safety follow-up action.                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- clinical, clinical or pharmacovigilance data                                                                                                                                                               |            |            |             |                                                                                                                                                                                                                                                                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IG/0092/G | This was an application for a group of variations. C.I.9.a - Changes to an existing pharmacovigilance system as described in the DDPS - Change in the QPPV C.I.9.h - Changes to an existing pharmacovigilance system as described in the DDPS - Other change(s) to the DDPS that does not impact on the operation of | 08/08/2011 | n/a        |             |                                                                                                                                                                                                                                                                          |
| II/0032   | to revise specification limits for the active substance. B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                      | 23/06/2011 | 23/06/2011 |             |                                                                                                                                                                                                                                                                          |
| IB/0033   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                           | 20/06/2011 | n/a        | SmPC and PL |                                                                                                                                                                                                                                                                          |
| II/0031   | Update of sections 4.4 \"Special Warnings and precautions for use, and 4.8 \"Undesirable effects\" of the SmPC to reflect the risk of thrombosis including pulmonary embolism as requested by CHMP following the evaluation of PSUR 5. The Package Leaflet has                                                          | 19/05/2011 | 17/06/2011 | SmPC and PL | The cumulative review of thrombosis and embolism resulting from the evaluation of PSUR 5 identified 17 cases of thrombosis and 9 cases of pulmonary embolism (PE) with fatal outcome in four cases of PE. Based on the absence of ADRs of embolism and thrombosis in the |

<div style=\"page-break-after: always\"></div>

|           | been updated accordingly. C.I.3.b - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under Article 45/46, or amendments to reflect a Core SPC - Change(s) with new additional data submitted by the MAH                                                                                                                                                                                                                                                                                        |            |            |                                  | Mircera clinical database and considering that frequencies based on reporting rates from a spontaneous reporting system should not be used to assign frequency categories, the MAH has reported \"frequency unknown\" for embolism and thrombosis in Section 4.8 of the SmPC, and included thrombosis as a serious cardiovascular event in section 4.4 when haemoglobin concentrations are increased beyond 12g/dl. The Package Leaflet has been updated accordingly.                                                                         |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0030/G | This was an application for a group of variations. C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation C.I.7.b - Deletion of - a strength                                                                                                                                                                                                                                                                                                                                                                                         | 11/02/2011 | n/a        | SmPC, Annex II, Labelling and PL | The MAH has applied to split and amend the wording in the annexes for multipack presentations as well as to delete all vials and some pre-filled syringe presentations. Annex II.B has also been updated to delete the DDPS version number as per the latest QRD template.                                                                                                                                                                                                                                                                  |
| II/0027   | Update of section 4.2 of the SmPC to introduce a new dosing schedule of once-monthly subcutaneous administration of Mircera in patients who are not on dialysis and not currently treated with an erythropoiesis stimulating agent, based on the results of study NH20052. Sections 4.8 and 5.1 of the SmPC were also updated to reflect the new data. The Package Leaflet has been updated accordingly. Minor editorial changes to Annex II were also introduced. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre- | 22/07/2010 | 26/08/2010 | SmPC, Annex II and PL            | Following the results of study NH20052 comparing Mircera administered subcutaneously (sc) once every 4 weeks (153 patients) to darbepoetin alfa treatment administered either once per week or once every 2 weeks (154 patients) during a 20-week correction period and an 8-week evaluation period, the MAH submitted a type II variation to updated section 4.2 of the SmPC to include a new dosing schedule of once monthly sc administration of Mircera. Sections 4.8 and 5.1 were also updated to reflect the data from study NH20052. |
| IB/0029   | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 23/08/2010 | n/a        | SmPC and PL                      | Inclusion of \"anaphylactic reactions\" as an adverse reaction in section 4.8 of the SmPC and in the Package Leaflet as a                                                                                                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         | PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |            |            |             | follow-up action to the assessment concerning Mircera PSUR 4 (Period 20.1.09 - 19.07.09).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0028 | C.I.3.a - Implementation of change(s) requested following the assessment of an USR, class labelling, a PSUR, RMP, FUM/SO, data submitted under A 45/46, or amendments to reflect a Core SPC - Changes with NO new additional data are submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 22/07/2010 | n/a        | SmPC and PL | Inclusion in the SmPC and PL of all ESAs agents of a statement agreed in December 2009 by the PhVWP and the CHMP to allow identification and traceability of all epoetin products.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| II/0022 | This variation concerns an update of the SmPC following the completion of a class safety review by the PhVWP and the CHMP. As a result, CHMP requested to update SmPC section 4.4 to include more information on pure red cell aplasia (PRCA) in patients with hepatitis C treated with Interferon, Ribavirin and Epoetin, as well as SmPC section 5.1 to include additional data on the Cochrane meta-analysis and the effects of epoetins in cancer patients. Additionally, following the class label text describing the Cochrane analysis in section 5.1 the following product-specific wording has been implemented: \" Mircera is not approved for treatment of patients with chemotherapy induced anaemia (see section 4.1), no patiens treated with Mircera were part of this data analysis\". The Patient Leaflet has been amended to reflect the increased risk of thromboembolic events in cancer | 22/04/2010 | 04/06/2010 | SmPC and PL | As a result of the discussion of the updated risk management plans (RMPs) and the results of the Cochrane meta-analysis it was agreed at the PhVWP/CHMP meeting in September 2009 that all MAHs for epoetins should submit a type II variation to amend the summary of product characteristics (SmPC). Information with respect to the results of the Cochrane meta-analysis on the effects of epoetins in cancer patients and to the occurrence of PRCA in patients with Hepatitis C treated with Interferon, Ribavirin and Epoetin should be included into the SmPC. The amendments of Sections 4.4 and 5.1 of the SmPC have been implemented as recommended by the PhVWP / CHMP. Additional product specific wording has been implemented to section 5.1. The Patient Leaflet has also been amended to reflect the increased risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin and the risk of anaemia worsening in patients treated with interferon and |

<div style=\"page-break-after: always\"></div>

|         | patients receiving recombinant human erythropoietin and the risk of anaemia worsening in patients treated with interferon and ribavirin (e.g. patient with hepatitis C). Update of Summary of Product Characteristics and Package Leaflet         |            |            |          | ribavirin (e.g. patient with hepatitis C).                                                                                                                                                                                                                                                                                                                                                                                              |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026 | Roche - Update of the detailed description of the pharmacovigilance system (version 4.1). Annex II has been updated accordingly. In addition, Annex II has been updated in line with the latest QRD templates. Update of DDPS (Pharmacovigilance) | 18/03/2010 | 29/04/2010 | Annex II | With this variation the MAH submitted a new version of the DDPS (core version 4.1) in accordance with the current Pharmacovigilance guideline. After assessing the documentation the CHMP concluded that the submitted DDPS contained all required elements. Consequently, Annex II has been updated with the new version number of the agreed core DDPS. In addition, Annex II has been updated in line with the latest QRD templates. |
| II/0024 | To implement changes to the analytical methods and release specifications. Quality changes                                                                                                                                                        | 21/01/2010 | 04/02/2010 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| II/0023 | To implement changes to the cultivation process for the drug substance and related changes. Quality changes                                                                                                                                       | 21/01/2010 | 04/02/2010 |          |                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| IB/0025 | To change the storage condition of the Mircera active substance. IB_17_b_Change in the storage conditions for the active substance                                                                                                                | 22/12/2009 | n/a        |          |                                                                                                                                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| IB/0021   | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                      | 25/09/2009   | 25/09/2009   | SmPC, Labelling and PL   |                 |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|-----------------|
| IB/0020   | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                      | 25/09/2009   | 25/09/2009   | SmPC, Labelling and PL   |                 |
| IB/0019   | IB_41_a_02_Change in pack size - change in no. of units outside range of appr. pack size                                                      | 25/09/2009   | 25/09/2009   | SmPC, Labelling and PL   |                 |
| II/0013   | The MAH applied for a reduction of the shelf life for the vials and reduced time for room temperature storage for the vials.                  | 19/02/2009   | 07/04/2009   | SmPC and PL              | Quality changes |
| II/0012   | to extend the shelf life for the prefilled syringes and patient convenience room temperature storage for pre-filled syringes. Quality changes | 19/02/2009   | 07/04/2009   |                          |                 |
| N/0011    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                              | 22/01/2009   | n/a          | PL                       |                 |
| IA/0015   | IA_08_b_01_Change in BR/QC testing - repl./add. manuf. responsible for BR - not incl. BC/testing                                              | 08/01/2009   | n/a          | Annex II and PL          |                 |
| IA/0014   | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                      | 06/01/2009   | n/a          |                          |                 |

<div style=\"page-break-after: always\"></div>

| X/0001   | Annex I_2.(c) Change or addition of a new strength/potency Change to one of the sites responsible for the testing of the biological activity for the drug product Change(s) to the test method(s) and/or specifications for the finished product   | 26/06/2008 23/07/2009   | 05/09/2008 30/07/2008   | II/0018   |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------|-------------------------|-----------|
| II/0017  | To provide supporting information on the reprocessing of the active substance. To update analytical methods for the control of the active substance. Change(s) to the manufacturing process for the active substance                               | 23/07/2009              | 30/07/2008              |           |
| II/0010  | Scale-up the drug substance manufacturing process. Change(s) to the manufacturing process for the active substance                                                                                                                                 | 24/07/2008              | 29/07/2008              |           |

<div style=\"page-break-after: always\"></div>

| II/0009   | Addition of analytical method to the release specification of the active substance. Change(s) to the test method(s) and/or specifications for the active substance                                                                                    | 24/07/2008   | 29/07/2008   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008   | scale up of manufacturing process for epoetin beta Change(s) to the manufacturing process for the active substance                                                                                                                                    | 30/05/2008   | 11/06/2008   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0007   | change of a storage eluent for chromatographic column Change(s) to the manufacturing process for the active substance                                                                                                                                 | 30/05/2008   | 11/06/2008   |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0005   | The MAH has applied to amend section 4.2 and 5.2 of the SPC to include the results of a clinical study report on the effect of severe hepatic impairment on the pharmacokinetics of Mircera (RO0503821). Update of Summary of Product Characteristics | 19/03/2008   | 23/04/2008   | SmPC                   | SPC sections 4.2 has been amended to include the statement: \"No adjustments of the starting dose nor of the dose modification rules are required in hepatic impaired patients\" following the results of a clinical study report on the effect of severe hepatic impairment on the pharmacokinetics of Mircera (RO0503821). In section 5.2, the following statement has also been added \"In a single dose study, after IV administration, the pharmacokinetics of MIRCERA are similar in patients with severe hepatic impairment as compared to healthy subject\". |
| II/0002   | Update of Summary of Product Characteristics and Package Leaflet                                                                                                                                                                                      | 24/01/2008   | 05/03/2008   | SmPC, Labelling and PL | This variation primarily concerns an update of the SPC following the completion of a class safety review by the PhVWP and the CHMP. The safety review was initiated because recent data show a consistent unexplained excess                                                                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                    |            |            | mortality in cancer patients with anaemia treated with epoetins, and that treatment of anaemia with epoetins in patients with chronic kidney disease to achieve relatively high target haemoglobin concentrations may be associated with an increase in the risk of mortality and cardiovascular morbidity. As a result, the main changes being implemented are: i) in section 4.1, to highlight that epoetins should be used only if associated with symptoms, ii) in Section 4.2 to establish a uniform target haemoglobin range for all epoetins, iii) in Section 4.4 to mention the observed negative benefit risk balance in patients treated with high target haemoglobin concentrations, and iv) in section 5.1 to include the relevant results of the trials triggering the safety review. The package leaflet has been updated accordingly. In addition, minor details in the labelling have been updated.   |
|---------|----------------------------------------------------------------------------------------------------|------------|------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0003 | Change(s) to the manufacturing process for the active substance                                    | 21/02/2008 | 25/02/2008 |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| IB/0004 | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient | 01/02/2008 | n/a        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |